![](/wp-content/uploads/2019/03/antolrx-pfizer-announcement.png)
$599
Pfizer Licenses T1DM Immunotherapy From AnTolRx
AnTolRx, a privately held biotech company, announced Pfizer has exercised its option to license AnTolRx’s antigen-specific immunotherapy for T1DM. According to the press release, AnTolRx will receive an up-front payment and is eligible for milestone and royalty payments. The specific financial terms were not disclosed. Below, FENIX provides thoughts on the AnTolRx opportunity in the context of other T1DM immunotherapies in development.